What are the basic dosing details for Afrezza (inhaled insulin), including the number of insulin units per cartridge and how many cartridges are required for a given dose?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Afrezza Dosing Basics: Cartridge Units and Administration

Afrezza inhaled insulin cartridges are available in three fixed-dose strengths: 4 units (blue), 8 units (green), and 12 units (purple), with each cartridge containing a single dose that is fully consumed upon inhalation. 1

Cartridge Specifications

  • Each cartridge delivers one complete dose - there are no partial doses or multiple uses per cartridge 2, 3, 4
  • Three available strengths:
    • 4-unit cartridge (blue)
    • 8-unit cartridge (green)
    • 12-unit cartridge (purple) 3, 4, 5

Dose Combinations for Higher Requirements

  • For doses exceeding 12 units, multiple cartridges must be used in combination 3, 4
  • Example combinations:
    • 16 units = one 12-unit + one 4-unit cartridge
    • 20 units = one 12-unit + one 8-unit cartridge
    • 24 units = two 12-unit cartridges 4

Clinical Context and Limitations

  • Afrezza is a prandial (mealtime) insulin only - it must be combined with basal insulin in type 1 diabetes and cannot be used for basal coverage 1, 5
  • The fixed-dose increments (4,8,12 units) represent a significant limitation compared to injectable insulins that allow single-unit titration 2, 3
  • Ultra-rapid pharmacokinetics: onset within 5 minutes, peak at 1-2 hours, duration 3-4 hours - faster than subcutaneous rapid-acting analogs 3, 4, 5

Important Caveats

  • Single-unit increment dosing is not possible - patients requiring precise titration may face challenges with the fixed 4-unit increments 2, 3
  • Contraindicated in chronic lung disease (asthma, COPD) and active smokers 1, 5
  • Cost consideration: Afrezza inhalation cartridges have substantially higher cost per 1,000 units ($1,503 AWP, $1,298 NADAC) compared to injectable rapid-acting insulins 1
  • Not suitable for diabetic ketoacidosis or as basal insulin replacement 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Future prospect of insulin inhalation for diabetic patients: The case of Afrezza versus Exubera.

Journal of controlled release : official journal of the Controlled Release Society, 2015

Research

Technosphere insulin: an inhaled prandial insulin product.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2010

Research

A review of inhaled technosphere insulin.

The Annals of pharmacotherapy, 2010

Research

Afrezza: An inhaled approach to insulin delivery.

Journal of the American Association of Nurse Practitioners, 2015

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.